Pfizer

WHO emergency COVID-19 vaccine listing aims to lift access in poor countries

January 2, 2021January 1, 2021 The African Mirror BioNTech, COVID-19 vaccine, Pfizer, poor countries, WHO

JOHN MILLER THE World Health Organization on Thursday listed Pfizer and BioNTech’s COVID-19 vaccine for emergency use, in a move

COVID-19

WHO expects decisions on Pfizer, Moderna, AstraZeneca vaccines in weeks

December 12, 2020December 11, 2020 The African Mirror AstraZeneca, COVID-19 vaccines, Moderna, Pfizer

THE World Health Organization expects to make decisions on whether to give emergency use approval to COVID-19 vaccines from Pfizer,

COVID-19

Pfizer, Moderna, AstraZeneca: Which COVID-19 vaccine could reach developing countries first?

December 9, 2020December 8, 2020 The African Mirror AstraZeneca, COVID-19, Moderna, Pfizer, vaccine

THIN LEI WIN MARGARET Keenan, a 90-year-old grandmother, on Tuesday became the first person in the world to receive the

COVID-19

Here is how the world reacted to Britain’s announcement that its COVID-19 vaccine rollout will begin next week

December 2, 2020December 2, 2020 The African Mirror BioNTech, COVID-19 vaccine, Pfizer, vaccine

BRITAIN has become the first country in the world to approve the COVID-19 vaccine developed by U.S. drugmaker Pfizer and

COVID-19

Pfizer, Moderna, AstraZeneca: Which COVID-19 vaccine could reach developing countries first?

November 27, 2020November 26, 2020 The African Mirror AstraZeneca, COVID-19 vaccine, Moderna, Pfizer

THIN LEI WIN PHARMACEUTICAL companies are racing to produce a vaccine against COVID-19 to roll out in early 2021 but

COVID-19

Oxford COVID-19 trial will look at interim Phase III data after 53 infections – investigator

November 20, 2020November 19, 2020 The African Mirror AstraZeneca, BioNTech, COVID-19 trial, Oxford University, Pfizer, Phase III data, vaccine trials

ALISTAIR SMOUT and KATE KELLAND OXFORD University will start an initial analysis of data from its late-stage trial of the

COVID-19

J&J starts two-dose trial of its COVID-19 vaccine candidate

November 16, 2020November 16, 2020 The African Mirror Ad26COV2, BioNTech, COVID-19 vaccine, Johnson & Johnson, one-dose trial, Pfizer

KATE KELLAND JOHNSON & JOHNSON has launched a new large-scale late-stage trial to test a two-dose regimen of its experimental

COVID-19

South Africa should aim to cover 10% of population via COVAX, advisors say

November 12, 2020November 19, 2020 The African Mirror 10% of population, COVAX, global coronavirus vaccine scheme, Pfizer, vaccines

ALEXANDER WINNING SOUTH Africa should aim to cover 10% of its population via a global coronavirus vaccine scheme while also

NEWS

‘Great day for humanity’: Pfizer says COVID-19 vaccine over 90% effective

November 10, 2020November 9, 2020 The African Mirror 90% effective, BioNTech SE, COVID-19 vaccine, Pfizer

MICHAEL ERMAN and JULIE STEENHUYSEN PFIZER Inc’s experimental COVID-19 vaccine is more than 90% effective based on initial trial results,

COVID-19

Kenya joins global trial of Oxford University’s COVID-19 vaccine

October 31, 2020October 30, 2020 The African Mirror AstraZeneca, BioNTech, ChAdOx1 nCoV-19, Kenya, Pfizer

KENYA has joined the global clinical trial of Oxford University’s vaccine candidate against the new coronavirus, the state medical research

WHO emergency COVID-19 vaccine listing aims to lift access in poor countries

WHO expects decisions on Pfizer, Moderna, AstraZeneca vaccines in weeks

Pfizer, Moderna, AstraZeneca: Which COVID-19 vaccine could reach developing countries first?

Here is how the world reacted to Britain’s announcement that its COVID-19 vaccine rollout will begin next week

Pfizer, Moderna, AstraZeneca: Which COVID-19 vaccine could reach developing countries first?

Oxford COVID-19 trial will look at interim Phase III data after 53 infections – investigator

J&J starts two-dose trial of its COVID-19 vaccine candidate

South Africa should aim to cover 10% of population via COVAX, advisors say

‘Great day for humanity’: Pfizer says COVID-19 vaccine over 90% effective

Kenya joins global trial of Oxford University’s COVID-19 vaccine

Press Council

Contact Details

Quick Links